Patent ID: 7931890

Claim:
A composition for effecting therapy of a bacterial infectious disease in a patient, comprising: (A) a first conjugate comprising a bispecific antibody or bispecific antigen-binding antibody fragment and a first therapeutic agent, wherein the bispecific antibody or fragment selectively binds to (i) a bacterial antigen selected from the group consisting of Streptococcus agalactiae, Legionella pneumophilia, Streptococcus pyogenes, Esherichia coli, Neisseria gonorrhosae, Neisseria meningitides, Pneumococcus, Hemophilis influenzae B, Treponema pallidum , Lyme disease spirochetes, Pseudomonas aeruginosa, Mycobacterium, leprae, Brucella abortus , and Mycobacterium tuberculosis ; and (B) optionally, a clearing agent; and (C) a second conjugate comprising a low molecular weight hapten and a second therapeutic agent, wherein the bispecific antibody or fragment binds to the hapten or the second therapeutic agent and wherein the second therapeutic agent is selected from the group consisting of a drug-polymer conjugate, a PEG-drug conjugate, and a drug-liposome conjugate.